NCT06737731View on ClinicalTrials.gov

A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 21, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

July 31, 2027

Conditions
Malignant Solid Tumors
Interventions
DRUG

SHR-1681

SHR-1681 for Injection will be administrated per dose level in which the patients are assigned.

Trial Locations (1)

200433

RECRUITING

Shanghai Dongfang Hospital, Shanghai

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY